The home-grown vaccine has been developed by the Nha Trang-based Institute of Vaccines and Medical Biologicals (IVAC) and the Hanoi Medical University since last May, using primary chicken embryo cell culture, a technique the institute used previously to successfully produce seasonal flu vaccines.
COVIVAC has undergone pre-clinical trials in India, the US, and Vietnam, VNA quoted IVAC Director Dr Duong Huu Thai said. He added that the results showed that it satisfies all conditions to be tested on humans.
The vaccine candidate demonstrated high immunogenicity during pre-clinical trials. It was created based on studies of new SARS-CoV-2 strains, according to Dr Pham Van Tac, Director of the Ministry of Health’s Administration of Science Technology and Training.
VNA reported that there will be two phases in the trial, with the first conducted on five groups of volunteers totalling 120 people. Each group will be given two shots 28 days apart, with doses of either 1mcg, 3mcg, or 10mcg.
IVAC facilities will be able to provide from 6 million to 30 million doses of COVIVAC vaccine yearly.
The COVIVAC vaccine can be preserved in temperature conditions from 2-8 degrees Celsius while other international vaccines must be stored at -70 degrees Celsius.
The volunteers, aged 18 to 59, has been recruited by the research team.
The first shot is scheduled to be injected at the Hanoi Medical University in February. - The Vietnam News/Asian News Network
Did you find this article insightful?
92% readers found this article insightful